Competitive Advantages
- Establishes GAS5 a circulating biomarker in blood, urine, or saliva
- Easy integration into routine care to assess risk of developing diabetes
- Non-invasive biomarker that predicts pre-diabetic and diabetic conditions
Summary
Our inventors have identified GAS5, an RNA-based biofluid marker for prediction and management of diabetes. GAS5 is a long non-coding RNA that has been found to have markedly reduced levels in serum from diabetic patients. Testing has demonstrated that GAS5 directly affects multiple insulin-responsive genes related to glucose metabolism and uptake. This study also establishes GAS5 as an circulating biomarker in blood, saliva and urine for early detection and diagnosis of pre-diabetes and in diabetes control. The invention is non-invasive and can be efficiently incorporated into standard care for diabetes.
qPCR Analysis of Gas5 from Obese Non-Diabetic, Obese-Diabetic and Lean Non-Diabetic Subjects
Desired Partnerships
- License
- Sponsored Research
- Co-Development